Privia Health Group, Inc. revised earnings guidance for the year 2023. For the year, the company expects revised GAAP revenue of Mid to High End compared to previously expected GAAP revenue to be in the range of $1,550 million to $1,650 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.37 USD | +0.64% | +7.82% | -24.58% |
May. 30 | Baird Starts Privia Health Group With Outperform Rating, $23 Price Target | MT |
May. 20 | Barclays Adjusts Price Target on Privia Health to $19 From $22, Maintains Equalweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.58% | 2.06B | |
+25.52% | 87.77B | |
-24.52% | 70.35B | |
-5.56% | 25.03B | |
+4.31% | 17.73B | |
-14.25% | 16.31B | |
+2.97% | 15.48B | |
+70.11% | 13.52B | |
+79.20% | 13.01B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- PRVA Stock
- News Privia Health Group, Inc.
- Privia Health Group, Inc. Revises Earnings Guidance for the Year 2023